Skip to main content

Table 5 Effects of metformin on ventricular arrhythmias: reports from clinical trials

From: Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient

Model

Type of study/No. of patients/FU

Metformin (dose/duration)

Key results and major findings

Interpretation

References

DM patients with CAD monitored via 24-h Holter monitor

(mean age 55)

Randomized crossover design/19 patients/2 weeks

Metformin 500 mg BID for 2 weeks

- <-> PVC/NSVT per minute of ischemia

Metformin did not reduce PVC/NSVT in diabetic CAD patients

[94]

Hospitalized DM patients with AMI

(mean age 56)

Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI

Various doses

- <-> 28-days VT/VF incidence

Metformin alone or in combination with other anti-DM drugs was not associated with decreased 28-day post AMI VT/VF incidence

[56]

  1. AMI acute myocardial infarction, CAD coronary artery disease, DM diabetes mellitus, PVC/NSVT premature ventricular contraction/non-sustained ventricular tachycardia, VT/VF ventricular tachycardia/ventricular fibrillation
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840